The phase I clinical trial was to evaluate the safety and tolerability of the OBI-858 treatment for subjects with moderate to severe frown lines form low doses to high doses. Initial results showed improvement in the degree of frown lines on the face, as rated by both the trial physicians and the subjects themselves. Results of Phase 1 clinical trial showed the product was safe and well-tolerated.
